Clinical Trials Browser

Not yet recruiting × Brain Neoplasms × aflutinib × Clear all

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Phase 2 Not yet recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06483672 2024-07-03

LungBrain001

Phase 2 Not yet recruiting

Adenocarcinoma of Lung, Brain Neoplasms

NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung